한글목차

세계의 방사성 표지 ADME 시험 시장의 미래는 바이오 제약 기업 및 정부·학술기관 시장에서의 기회로 유망시되고 있습니다. 세계의 방사성 표지 ADME 시험 시장은 2025-2031년에 CAGR 12.1%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 의약품 개발비의 증가, 맞춤형 의료에 대한 수요 증가, 종양학과 신경학에서 연구의 증가입니다.

Lucintel은 유형별로는 C-14가 예측 기간 중 높은 성장세를 보일 것으로 예상하고 있습니다.

용도별로는 바이오 제약사가 더 높은 성장을 이룰 것으로 예측됩니다.

지역별로는 아시아태평양이 예측 기간 중 가장 높은 성장을 보일 것으로 예측됩니다.

방사성 표지 ADME 시험 시장의 새로운 동향

방사성 표지 ADME 테스트 시장은 기술 발전, 규제 변화, 소비자 선호도 변화로 인해 몇 가지 새로운 동향이 나타나고 있습니다. 이러한 추세는 제약회사들이 의약품 개발에 접근하는 방식을 재구성하고 있으며, 정확성, 효율성, 개인화된 치료에 큰 초점을 맞추었습니다.

• 이미징 기술의 발전: PET 및 SPECT와 같은 첨단 이미징 기술의 사용은 방사성 표지 ADME 시험에 혁명을 일으키고 있습니다. 이러한 기술은 체내 약물 분포를 실시간으로 고해상도로 영상화하여 약동학에 대한 보다 정확한 인사이트를 제공합니다. 이러한 추세는 조직내 약물의 거동을 이해하는 것이 치료 효과에 중요한 종양학 및 기타 치료 분야에서 특히 유용합니다.
• 데이터 분석의 인공지능 통합: ADME 데이터 분석에서 AI와 ML의 통합이 점점 더 두드러지고 있으며, AI 기반 알고리즘은 대규모 데이터세트를 처리하여 패턴을 식별하고 약물의 거동을 높은 정확도로 예측할 수 있습니다. 이러한 추세는 의약품 개발 기간을 단축하고, 비용을 절감하며, 체내 약물 상호 작용을 보다 정확하게 모델링하여 치료 결과를 개선할 수 있게 해줍니다.
• 맞춤의료의 중요성: 개인의 유전자 프로파일과 대사 행동에 따라 약물 치료를 조정하는 맞춤의료의 중요성이 강조되고 있습니다. 방사성 표지 ADME 검사는 개인마다 약물이 어떻게 대사되는지에 대한 중요한 데이터를 제공하므로 이러한 변화에서 매우 중요합니다. 이러한 추세는 특정 환자군의 약물 반응에 대한 인사이트를 제공할 수 있는 보다 정교한 ADME 시험에 대한 수요를 촉진하고 있습니다.
• 제약기업과 학술기관의 협력 증가: 제약기업과 학술연구기관과의 협력이 증가하는 추세입니다. 이러한 파트너십은 ADME 시험을 위한 새로운 방사성동위원소 추적자 및 바이오마커를 개발하는 데 도움이 되고 있습니다. 이러한 협력은 업계 전문 지식과 학술연구를 결합하여 혁신의 속도를 가속화하고 의약품 개발에서 생성되는 데이터의 품질을 향상시킬 수 있습니다.
• 임상시험 아웃소싱의 성장: 방사성 표지 ADME 시험 시장에서는 CRO(임상시험 수탁기관)에 임상시험을 아웃소싱하는 것이 일반화되고 있습니다. 제약사들은 비용 효율성과 전문 지식에 대한 접근성을 이유로 CRO에 대한 의존도를 높이고 있습니다. 이러한 추세는 제약사들이 복잡한 임상시험을 수행함에 있으며, 외부의 전문지식을 활용하는 한편, 연구 프로세스를 간소화하고 핵심 사업 분야에 집중할 수 있도록 돕고 있습니다.

AI의 통합, 방사성 추적자의 발전, 맞춤형 의료, 안전성의 중요성, CRO의 부상과 같은 새로운 동향은 방사성동위원소를 이용한 ADME 시험 시장을 크게 변화시키고 있습니다. 이러한 추세는 의약품 개발의 효율성, 정확성, 안전성을 향상시키고, 새로운 치료법 시장 출시 시간을 단축하여 이 시장의 세계 확대에 기여하고 있습니다.

라디오 라벨 ADME 테스트 시장의 최근 동향

방사성 표지 ADME 테스트 시장은 의약품 개발에서 이 중요한 분야의 끊임없는 진화를 반영하여 다양한 발전을 거듭해 왔습니다. 이러한 발전은 기술 발전, 규제 변화, 정확한 약동학 데이터에 대한 수요 증가에 의해 주도되고 있습니다.

• 새로운 방사성동위원소 추적자의 개발: 최근 새로운 방사성동위원소 추적자의 개발 동향은 약물의 분포, 대사 및 배설을 연구할 수 있는 능력을 향상시키고 있습니다. 이러한 새로운 추적자는 민감도와 특이성을 향상시켜 체내 약물을 보다 정확하게 추적할 수 있게 되었습니다. 이 개발은 표적 조직에서 약물의 거동을 이해하는 것이 치료 효과에 매우 중요한 종양학 및 중추신경계(CNS) 질환에 특히 유용합니다.
• 이미징 기술의 발전: PET-MRI 및 PET-CT와 같은 새로운 이미징 기술의 통합으로 방사성동위원소를 이용한 ADME 시험의 데이터 품질이 향상되고 있습니다. 이러한 하이브리드 이미징 기술은 약물의 분포와 대사에 대한 상세한 다차원 이미지를 제공하여 약물과 인체와의 상호 작용에 대한 보다 종합적인 시각을 제공합니다. 이 개발로 인해 의약품 개발 속도가 빨라지고 임상시험의 정확도가 향상되고 있습니다.
• 첨단 시험법에 대한 규제적 지원: 미국, 독일, 일본을 포함한 많은 국가에서 첨단 방사성동위원소를 이용한 ADME 시험법 사용을 지원하는 규제적 프레임워크를 도입하고 있습니다. 이러한 규제는 신약 승인을 용이하게 하고, 혁신적인 검사 기술을 임상시험에 통합할 수 있는 합리적인 경로를 제공합니다. 이러한 발전은 제약회사들 사이에서 방사성동위원소를 이용한 시험에 대한 신뢰도를 높이고 있습니다.
• 의약품 개발에 대한 투자 증가: 의약품 연구개발에 대한 투자 증가는 방사성동위원소를 이용한 ADME 시험의 확대에 기여하고 있습니다. 제약사들은 임상시험에 앞서 신약 후보물질의 약동학을 더 자세히 이해하기 위해 신약 후보물질의 약동학 연구에 많은 자원을 투입하고 있습니다. 이러한 추세는 방사성동위원소를 이용한 ADME 시험 프로바이더들에게 확대되는 고객 기반에 특화된 서비스를 제공할 수 있는 새로운 기회를 창출하고 있습니다.
• 비침습적 검사에 대한 관심: 혈액 기반 바이오마커와 약물 흡수 및 배설을 모니터링하는 웨어러블 기술 등 방사성동위원소를 이용한 ADME 검사를 위한 비침습적 검사 방법에 대한 관심이 증가하고 있습니다. 이러한 방법들은 비침습적인 데이터 수집 방법을 제공하여 환자의 편안함을 개선하는 동시에 약물의 거동에 대한 귀중한 인사이트를 제공합니다. 이러한 개발로 인해 ADME 시험은 더욱 환자 친화적이 되어 임상시험에서 ADME 시험이 더욱 매력적으로 다가오고 있습니다.

이미징, 방사성 추적자 개발, 공동 연구 구상, 규제 개선, CRO 서비스 확대 등의 최근 동향은 모두 방사성 표지 ADME 시험 시장의 성장에 기여하고 있습니다. 이러한 개발은 의약품 시험의 효율성과 정확성을 향상시키고, 궁극적으로 의약품 개발 속도를 가속화하여 환자에게 보다 안전한 치료를 보장할 수 있습니다.

목차

제1장 개요

제2장 세계의 방사성 표지 ADME 시험 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석, 2019-2031년

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 방사성 표지 ADME 시험 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 방사성 표지 ADME 시험 시장 : 유형별
  • C-14
  • H-3
  • 기타
• 세계의 방사성 표지 ADME 시험 시장 : 용도별
  • 바이오의약품 기업
  • 정부기관·학술기관
  • 기타

제4장 시장 동향과 예측 분석 : 지역별, 2019-2031년

• 세계의 방사성 표지 ADME 시험 시장 : 지역별
• 북미의 방사성 표지 ADME 시험 시장
• 유럽의 방사성 표지 ADME 시험 시장
• 아시아태평양의 방사성 표지 ADME 시험 시장
• 기타 지역의 방사성 표지 ADME 시험 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 방사성 표지 ADME 시험 시장의 성장 기회 : 유형별
  • 세계의 방사성 표지 ADME 시험 시장의 성장 기회 : 용도별
  • 세계의 방사성 표지 ADME 시험 시장의 성장 기회 : 지역별
• 세계의 방사성 표지 ADME 시험 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 방사성 표지 ADME 시험 시장의 커패시티 확대
  • 세계의 방사성 표지 ADME 시험 시장의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 기업 개요

• Charles River
• Eurofins Scientific
• Evotec
• Labcorp
• Sekisui Medical
• Xenotech(Bioivt)
• Qps
• Bioduro-Sundia
• Quotient Sciences
• Chelatec

영문목차

The future of the global radiolabelled ADME studies market looks promising with opportunities in the biopharmaceutical company and government and academic institute markets. The global radiolabelled ADME studies market is expected to grow with a CAGR of 12.1% from 2025 to 2031. The major drivers for this market are the increasing drug development cost, rising demand for personalized medicine, and increased research in oncology and neurology.

Lucintel forecasts that, within the type category, C-14 is expected to witness higher growth over the forecast period.

Within the application category, a biopharmaceutical company is expected to witness higher growth.

In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Radiolabelled ADME Studies Market

The radiolabelled ADME studies market is witnessing several emerging trends driven by technological advancements, regulatory changes, and evolving consumer preferences. These trends are reshaping how pharmaceutical companies approach drug development, with a greater focus on precision, efficiency, and personalized treatments.

• Advancement of Imaging Technologies: The use of advanced imaging technologies like PET and SPECT is revolutionizing Radiolabelled ADME studies. These techniques allow for real-time, high-resolution imaging of drug distribution within the body, offering more accurate insights into pharmacokinetics. This trend is particularly beneficial in oncology and other therapeutic areas where understanding drug behavior in tissues is critical for treatment efficacy.
• Integration of Artificial Intelligence in Data Analysis: The integration of AI and ML in analyzing ADME data is becoming increasingly prominent. AI-driven algorithms can process large datasets to identify patterns and predict drug behaviors with high accuracy. This trend is enhancing drug development timelines, reducing costs, and enabling more precise modeling of drug interactions in the body, leading to improved therapeutic outcomes.
• Focus on Personalized Medicine: There is a growing emphasis on personalized medicine, which tailors drug treatments based on individual genetic profiles and metabolic behaviors. Radiolabelled ADME studies are pivotal in this shift, as they provide critical data on how different individuals metabolize drugs. This trend is driving the demand for more sophisticated ADME studies that can offer insights into drug responses for specific patient populations.
• Increased Collaboration of Pharma and Academic Institutions: Increased collaborations between pharmaceutical companies and academic research institutions are a growing trend. These partnerships help in advancing the development of new radiolabelled tracers and biomarkers for ADME studies. By combining industry expertise with academic research, these collaborations accelerate the pace of innovation and improve the quality of data generated in drug development.
• Growth of Outsourcing in Clinical Trials: The outsourcing of clinical trials to contract research organizations (CROs) is becoming more common in the radiolabelled ADME studies market. Pharmaceutical companies are increasingly relying on CROs for conducting ADME studies due to cost-effectiveness and access to specialized knowledge. This trend is helping pharmaceutical companies streamline their research processes and focus on core business areas, while leveraging external expertise in conducting complex studies.

Emerging trends like AI integration, radiotracer advancements, personalized medicine, a focus on safety, and the rise of CROs are significantly reshaping the radiolabelled ADME studies market. These trends are improving efficiency, precision, and the overall safety of drug development, driving faster time-to-market for new treatments and contributing to the expansion of this market globally.

Recent Developments in the Radiolabelled ADME Studies Market

The radiolabelled ADME studies market has seen a variety of developments, reflecting the continuous evolution of this critical area of drug development. These developments are driven by technological advancements, regulatory changes, and the increasing need for accurate pharmacokinetic data.

• Development of New Radiolabelled Tracers: Recent advancements in the development of new radiolabelled tracers have enhanced the ability to study drug distribution, metabolism, and excretion. These new tracers offer improved sensitivity and specificity, enabling more precise tracking of drugs within the body. This development is particularly useful in oncology and central nervous system (CNS) disorders, where understanding drug behavior in targeted tissues is crucial for treatment efficacy.
• Advances in Imaging Techniques: The integration of novel imaging technologies such as PET-MRI and PET-CT is improving the quality of data in Radiolabelled ADME studies. These hybrid imaging techniques provide detailed, multi-dimensional images of drug distribution and metabolism, offering a more comprehensive view of how drugs interact with the human body. This development is accelerating the pace of drug development and improving the accuracy of clinical trials.
• Regulatory Support for Advanced Testing Methods: Many countries, including the United States, Germany, and Japan, are increasingly adopting regulatory frameworks that support the use of advanced radiolabelled ADME testing methods. These regulations facilitate the approval of new drugs and provide a streamlined pathway for integrating innovative testing technologies into clinical trials. This development is fostering greater confidence in radiolabelled studies among pharmaceutical companies.
• Growing Investment in Drug Development: Increased investment in pharmaceutical R&D is contributing to the expansion of Radiolabelled ADME studies. Pharmaceutical companies are allocating more resources to studying the pharmacokinetics of new drug candidates, as they seek to understand their behavior more thoroughly before clinical trials. This trend is creating new opportunities for radiolabelled ADME study providers to offer specialized services to a growing client base.
• Focus on Non-Invasive Testing: There is a growing interest in non-invasive testing methods for Radiolabelled ADME studies, including blood-based biomarkers and wearable technologies that monitor drug absorption and excretion. These methods provide a less invasive approach to collecting data, improving patient comfort while providing valuable insights into drug behavior. This development is making ADME studies more patient-friendly and increasing their appeal in clinical trials.

Recent developments such as technological advancements in imaging, radiotracer development, collaborative research initiatives, regulatory improvements, and the expansion of CRO services are all contributing to the growth of the radiolabelled ADME studies market. These developments are improving the efficiency and accuracy of drug testing, ultimately accelerating the pace of drug development and ensuring safer treatments for patients.

Strategic Growth Opportunities in the Radiolabelled ADME Studies Market

The radiolabelled ADME studies market offers significant strategic growth opportunities, particularly in applications related to drug development, precision medicine, and diagnostic imaging. These opportunities are being driven by the demand for more detailed pharmacokinetic data and the increasing use of advanced technologies in drug testing.

• Expansion in Oncology Drug Development: The growing focus on oncology drug development presents a major opportunity for Radiolabelled ADME studies. As cancer treatments become more targeted and personalized, radiolabelled studies are providing valuable insights into the distribution of therapeutic agents within tumor tissues. This application is enabling pharmaceutical companies to develop more effective and precise treatments, improving patient outcomes.
• Advancements in CNS Drug Development: The development of drugs targeting central nervous system (CNS) disorders is another area where Radiolabelled ADME studies are playing a critical role. These studies help researchers understand how drugs cross the blood-brain barrier and interact with brain tissues, providing crucial data for developing effective treatments for neurological diseases. This growth opportunity is attracting investments in radiolabelled ADME testing services.
• Personalized Medicine Applications: As personalized medicine continues to gain momentum, the demand for radiolabelled ADME studies tailored to individual genetic profiles is growing. These studies provide insights into how different individuals metabolize drugs, allowing for the development of more targeted therapies. The application of Radiolabelled ADME studies in personalized medicine is a key growth opportunity for the market.
• Technological Integration with Artificial Intelligence: The integration of AI and machine learning in analyzing Radiolabelled ADME study data is a significant growth opportunity. AI-driven data analysis can enhance the accuracy and efficiency of these studies, providing pharmaceutical companies with quicker insights into drug behavior. This technological advancement is making Radiolabelled ADME studies more cost-effective and faster, driving further adoption in drug development.
• Outsourcing of Radiolabelled ADME Studies: Outsourcing Radiolabelled ADME studies to contract research organizations (CROs) is becoming increasingly popular as pharmaceutical companies look to reduce costs and gain access to specialized expertise. This trend offers growth opportunities for CROs and testing service providers, allowing them to expand their service offerings and cater to a growing global market.

The radiolabelled ADME studies market is experiencing growth across multiple applications, particularly in oncology, neuroscience, drug safety, biopharmaceuticals, and early-stage drug development. These strategic growth opportunities will drive innovation in the market, ensuring more efficient and targeted therapies for patients and accelerating drug development timelines.

Radiolabelled ADME Studies Market Driver and Challenges

The radiolabelled ADME studies market is influenced by various technological, economic, and regulatory factors. These drivers and challenges significantly shape the market's development and the strategic decisions made by pharmaceutical companies and research organizations.

The factors responsible for driving the radiolabelled ADME studies market include:

1. Technological Advancements in Imaging and Tracer Development: The continuous advancement in imaging technologies like PET, SPECT, and MRI is a key driver of growth in the radiolabelled ADME studies market. These technologies enable more accurate and detailed tracking of drug behavior, making ADME studies more effective in assessing drug pharmacokinetics.

2. Increase in Drug Development Activities: The growing global pharmaceutical R&D activities are driving the demand for Radiolabelled ADME studies. As pharmaceutical companies focus on developing new and innovative therapies, the need for precise pharmacokinetic data to support drug approval processes is growing, driving the market for ADME testing services.

3. Government Support and Regulatory Frameworks: In many countries, government policies and regulatory support for the pharmaceutical and biotechnology sectors are driving growth in the radiolabelled ADME studies market. Regulatory frameworks that encourage the use of advanced testing methods are helping to accelerate the approval of new drugs and improve the quality of data obtained from ADME studies.

4. Growth in Precision Medicine: The rise of precision medicine is a significant driver of the radiolabelled ADME studies market. These studies are crucial for understanding how different patients metabolize drugs based on their genetic profiles, which is essential for developing personalized treatment options.

5. Global Expansion of Pharmaceutical Companies: As pharmaceutical companies expand their global presence, there is a growing demand for Radiolabelled ADME studies to understand drug behavior in diverse patient populations. This expansion is driving the market's growth by requiring more comprehensive and accurate data for drug development across multiple regions.

Challenges in the radiolabelled ADME studies market are:

1. High Costs of Radiolabelled ADME Studies: The high cost of conducting Radiolabelled ADME studies is a major challenge for pharmaceutical companies, especially for smaller firms with limited research budgets. The expense of producing radiolabelled tracers and conducting imaging studies can be prohibitive, limiting the number of studies conducted.

2. Regulatory Complexity and Approval Delays: The regulatory landscape for Radiolabelled ADME studies is complex, with varying requirements across different regions. These regulatory hurdles can lead to delays in study approval and increase the time and cost associated with bringing new drugs to market.

3. Limited Availability of Skilled Professionals: The specialized nature of Radiolabelled ADME studies requires skilled professionals, including radiochemists, pharmacologists, and imaging experts. The limited availability of qualified professionals in certain regions can create challenges in meeting the demand for these studies.

4. Ethical Concerns with Radiolabelled Testing: Ethical concerns related to the use of radioactive substances in human testing can pose challenges for Radiolabelled ADME studies. Public perceptions of the risks associated with radioactive materials may lead to regulatory scrutiny and limit the acceptance of these testing methods.

5. Technological Challenges in Imaging and Data Analysis: Despite advancements, challenges remain in the application of imaging technologies to Radiolabelled ADME studies. The accuracy of data obtained from imaging devices can be influenced by several factors, including the sensitivity of the tracers used and the ability to capture real-time data. These technological challenges can limit the effectiveness of Radiolabelled ADME studies and hinder market growth.

The radiolabelled ADME studies market is driven by advancements in technology, personalized medicine, and the growing demand for drug safety and regulatory compliance. However, challenges such as high costs, regulatory hurdles, and the limited availability of radiolabelled compounds must be addressed for the market to continue its growth.

List of Radiolabelled ADME Studies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiolabelled ADME studies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiolabelled ADME studies companies profiled in this report include-

• Charles River
• Eurofins Scientific
• Evotec
• Labcorp
• Sekisui Medical
• Xenotech (Bioivt)
• Qps
• Bioduro-Sundia
• Quotient Sciences
• Chelatec

Radiolabelled ADME Studies Market by Segment

The study includes a forecast for the global radiolabelled ADME studies market by type, application, and region.

Radiolabelled ADME Studies Market by Type [Value from 2019 to 2031]:

• C-14
• H-3
• Others

Radiolabelled ADME Studies Market by Application [Value from 2019 to 2031]:

• Biopharmaceutical Companies
• Government and Academic Institutes
• Others

Radiolabelled ADME Studies Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radiolabelled ADME Studies Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. It highlights recent developments by major radiolabelled ADME studies producers in key regions: the USA, China, India, Japan, and Germany.

• United States: The U.S. has seen notable progress in the radiolabelled ADME studies market with advancements in imaging technologies such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). These innovations have enabled more accurate and real-time tracking of drug distribution within the human body, providing enhanced data for pharmaceutical research and clinical trials. Additionally, the adoption of artificial intelligence (AI) and machine learning (ML) in analyzing ADME data has further advanced drug development processes, making them more efficient and precise.
• China: The Chinese radiolabelled ADME studies market is growing rapidly, fueled by significant investments in research and technological advancements in medical imaging. The Chinese government's support for biotechnology and healthcare initiatives has led to an expansion of facilities focused on radiolabelled compound testing. Moreover, collaborations between Chinese research institutes and global pharmaceutical companies have strengthened the research capabilities in the country, allowing for better drug development processes and improved understanding of pharmacokinetics.
• Germany: In Germany, the focus on precision medicine has driven the growth of the radiolabelled ADME studies market. Technological advancements in PET and SPECT imaging technologies have allowed for more detailed studies on drug metabolism and tissue distribution. Furthermore, Germany's regulatory framework is conducive to the adoption of innovative testing methods, encouraging pharmaceutical companies to utilize radiolabelled studies in their drug development pipeline. The country's well-established pharmaceutical and biotechnology industries have also spurred further research into this area.
• India: India has emerged as an important player in the radiolabelled ADME studies market, driven by increasing pharmaceutical R&D activities and an expanding healthcare infrastructure. The country has become a hub for clinical trials, with numerous international pharmaceutical companies conducting radiolabelled studies to understand drug metabolism and excretion. India's cost-effective research and development environment, combined with its growing expertise in pharmacokinetics, has made it an attractive location for global pharmaceutical companies.
• Japan: The Japanese radiolabelled ADME studies market has benefited from its advanced technological infrastructure and robust pharmaceutical industry. Japan has been a leader in developing new radiolabelled tracers and biomarkers for use in ADME studies. The country's regulatory support for new drug development and its commitment to advancing healthcare technologies have led to increased collaborations between academic institutions and pharmaceutical companies. Japan is also seeing growth in the demand for precision medicine, which further drives the need for more accurate ADME data.

Features of the Global Radiolabelled ADME Studies Market

Market Size Estimates: Radiolabelled ADME studies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Radiolabelled ADME studies market size by type, application, and region in terms of value ($B).

Regional Analysis: Radiolabelled ADME studies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the radiolabelled ADME studies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiolabelled ADME studies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radiolabelled ADME studies market by type (C-14, H-3, and others), application (biopharmaceutical companies, government and academic institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiolabelled ADME Studies Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Radiolabelled ADME Studies Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Radiolabelled ADME Studies Market by Type
  • 3.3.1: C-14
  • 3.3.2: H-3
  • 3.3.3: Others
• 3.4: Global Radiolabelled ADME Studies Market by Application
  • 3.4.1: Biopharmaceutical Companies
  • 3.4.2: Government and Academic Institutes
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Radiolabelled ADME Studies Market by Region
• 4.2: North American Radiolabelled ADME Studies Market
  • 4.2.1: North American Market by Type: C-14, H-3, and Others
  • 4.2.2: North American Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others
• 4.3: European Radiolabelled ADME Studies Market
  • 4.3.1: European Market by Type: C-14, H-3, and Others
  • 4.3.2: European Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others
• 4.4: APAC Radiolabelled ADME Studies Market
  • 4.4.1: APAC Market by Type: C-14, H-3, and Others
  • 4.4.2: APAC Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others
• 4.5: ROW Radiolabelled ADME Studies Market
  • 4.5.1: ROW Market by Type: C-14, H-3, and Others
  • 4.5.2: ROW Market by Application: Biopharmaceutical Companies, Government and Academic Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radiolabelled ADME Studies Market by Type
  • 6.1.2: Growth Opportunities for the Global Radiolabelled ADME Studies Market by Application
  • 6.1.3: Growth Opportunities for the Global Radiolabelled ADME Studies Market by Region
• 6.2: Emerging Trends in the Global Radiolabelled ADME Studies Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radiolabelled ADME Studies Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiolabelled ADME Studies Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Charles River
• 7.2: Eurofins Scientific
• 7.3: Evotec
• 7.4: Labcorp
• 7.5: Sekisui Medical
• 7.6: Xenotech (Bioivt)
• 7.7: Qps
• 7.8: Bioduro-Sundia
• 7.9: Quotient Sciences
• 7.10: Chelatec